Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt‐Jakob disease

Abstract Most suspected Creutzfeldt‐Jakob disease (CJD) cases are eventually diagnosed with other disorders. We assessed the utility of investigating Alzheimer's disease (AD) biomarkers and neurofilament light (NfL) in patients when CJD is suspected. The study cohort consisted of cerebrospinal fluid...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Zitianyu Wang, Victoria Lewis, Christiane Stehmann, Shiji Varghese, Matteo Senesi, Amelia McGlade, Laura J. Ellett, James D. Doecke, Dhamidhu Eratne, Dennis Velakoulis, Colin L. Masters, Steven J. Collins, Qiao‐Xin Li
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2024-01-01
Rangatū:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Ngā marau:	Alzheimer's disease amyloid beta 1‐42 cerebrospinal fluid biomarker Creutzfeldt‐Jakob disease differential diagnosis Elecsys
Urunga tuihono:	https://doi.org/10.1002/dad2.12548
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!